The Hypoxic-Ischemic Encephalopathy drugs in development market research report provides comprehensive information on the therapeutics under development for Hypoxic-Ischemic Encephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hypoxic-Ischemic Encephalopathy. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hypoxic-Ischemic Encephalopathy and features dormant and discontinued products.
GlobalData tracks 17 drugs in development for Hypoxic-Ischemic Encephalopathy by 16 companies/universities/institutes. The top development phase for Hypoxic-Ischemic Encephalopathy is preclinical with nine drugs in that stage. The Hypoxic-Ischemic Encephalopathy pipeline has 15 drugs in development by companies and two by universities/ institutes. Some of the companies in the Hypoxic-Ischemic Encephalopathy pipeline products market are: Chiesi Farmaceutici, Gedeon Richter and University of Maryland School of Medicine.
The key targets in the Hypoxic-Ischemic Encephalopathy pipeline products market include Microtubule Associated Protein Tau, Transient Receptor Potential Cation Channel Subfamily V Member 1, and G Protein Coupled Receptor 55.
The key mechanisms of action in the Hypoxic-Ischemic Encephalopathy pipeline product include Endothelin Receptor Type B Agonist with one drug in Phase II. The Hypoxic-Ischemic Encephalopathy pipeline products include four routes of administration with the top ROA being Intravenous and six key molecule types in the Hypoxic-Ischemic Encephalopathy pipeline products market including Cell Therapy, and Small Molecule.
Hypoxic-Ischemic Encephalopathy overview
Hypoxic-ischemic encephalopathy (HIE) is also known as neonatal encephalopathy, perinatal hypoxia, or birth asphyxia. It is a serious birth complication affecting full-term infants less commonly seen in childhood and adulthood. It is caused by loss of oxygen or reduced blood flow to the brain cells. The exact cause of HIE is unknown but brain dysfunction is observed in patients with this condition, causing seizures. Other non-seizure symptoms include cerebral palsy, vision disturbances, learning and attention disorders, and kidney issues. Diagnosis includes physical and laboratory examinations like MRI, EEG, APGAR scores, and abnormal fetal heartbeat. Management of seizures is the primary treatment option; other therapies include and hypothermia (cooling of the body) and symptomatic therapy.
For a complete picture of Hypoxic-Ischemic Encephalopathy’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
